Retraction: The Significance of Notch1 Compared with Notch3 in High Metastasis and Poor Overall Survival in Hepatocellular Carcinoma (PLoS ONE 8: 2 (e57382) DOI: 10.1371/journal.pone.0057382);The Significance of Notch1 Compared with Notch3 in High Metastasis and Poor Overall Survival in Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhou, Liang ^a   Zhang, Ning ^a   Song, Wenjie ^a   You, Nan ^a   Li, Qingjun ^a   Sun, Wei ^a   Zhang, Yong ^a   Wang, Desheng ^a   Dou, Kefeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V6 ANTIGEN; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; UROKINASE; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL VIABILITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84874571685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0301556     Document Type: Erratum

References (57)

1. Thomas MB, Zhu AX, (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: 2892-2899.
2. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
3. Zlobin A, Jang M, Miele L, (2000) Toward the rational design of cell fate modifiers: notch signaling as a target for novel biopharmaceuticals. Curr Pharm Biotechnol 1: 83-106.
4. Jang MS, Zlobin A, Kast WM, Miele L, (2000) Notch signaling as a target in multimodality cancer therapy. Curr Opin Mol Ther 2: 55-65.
5. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, et al. (2006) Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778-2784.
6. Yu B, Wei J, Qian X, Lei D, Ma Q, et al. (2012) Notch1 signaling pathway participates in cancer invasion by regulating MMPs in lingual squamous cell carcinoma. Oncol Rep 27: 547-552.
7. Wang J, Fu L, Gu F, Ma Y, (2011) Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 26: 1295-1303.
8. Gao J, Song Z, Chen Y, Xia L, Wang J, et al. (2008) Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis 40: 114-121.
9. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, et al. (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537.
10. Chu D, Li Y, Wang W, Zhao Q, Li J, et al. (2010) High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 17: 1337-1342.
11. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, et al. (2002) Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A 99: 3788-3793.
12. Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L, et al. (2009) Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 69: 1314-1323.
13. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L, (2006) Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res 26: 2123-2127.
14. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, et al. (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92: 1355-1357.
15. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, et al. (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-576.
16. Park JT, Li M, Nakayama K, Mao TL, Davidson B, et al. (2006) Notch3 gene amplification in ovarian cancer. Cancer Res 66: 6312-6318.
17. Zhang Z, Wang H, Ikeda S, Fahey F, Bielenberg D, et al. (2010) Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol 177: 1459-1469.
18. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, et al. (2004) Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-615.
19. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, et al. (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20: 685-693.
20. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M, et al. (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177: 1087-1094.
21. Chu D, Zhang Z, Zhou Y, Wang W, Li Y, et al. (2011) Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol 22: 2440-2447.
22. Parr C, Watkins G, Jiang WG, (2004) The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 14: 779-786.
23. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, et al. (2008) Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68: 5226-5235.
24. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, et al. (1996) Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 56: 1775-1785.
25. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
26. Huang H, Bhat A, Woodnutt G, Lappe R, (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
27. Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, et al. (2010) Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol 117: 409-416.
28. Kamstrup MR, Gjerdrum LM, Biskup E, Lauenborg BT, Ralfkiaer E, et al. (2010) Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 116: 2504-2512.
29. Mann CD, Bastianpillai C, Neal CP, Masood MM, Jones DJ, et al. (2012) Notch3 and hey-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS One 7: e51119.
30. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, et al. (2009) Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol 50: 969-979.
31. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, et al. (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24.
32. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, et al. (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 6: e24217.
33. Liu YJ, Yan PS, Li J, Jia JF, (2005) Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol 11: 6601-6606.
34. Kemler R, (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9: 317-321.
35. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20: 2417-2428.
36. Tsujii M, DuBois RN, (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501.
37. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, et al. (2001) E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71: 949-954; discussion 954-945.
38. Wells A, Yates C, Shepard CR, (2008) E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 25: 621-628.
39. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U, (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 105: 6392-6397.
40. Lim SO, Kim HS, Quan X, Ahn SM, Kim H, et al. (2011) Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol 9: 83.
41. Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, et al. (2011) Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer.
42. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, et al. (2002) Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833.
43. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, et al. (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66: 5338-5345.
44. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, et al. (2003) Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37: 138-162.
45. Dannenberg AJ, Subbaramaiah K, (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436.
46. Park K, Han S, Shin E, Kim HJ, Kim JY, (2006) Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32: 1093-1096.
47. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, et al. (2009) The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 69: 5039-5048.
48. Itoh Y, Nagase H, (2002) Matrix metalloproteinases in cancer. Essays Biochem 38: 21-36.
49. Zeng ZS, Cohen AM, Guillem JG, (1999) Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20: 749-755.
50. Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, et al. (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and-9 in human gliomas. Brain Tumor Pathol 21: 105-112.
51. Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C, et al. (2011) Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res 71: 277-286.
52. Chan-Hui PY, Weaver R, (1998) Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades. Biochem J 336 (Pt 3): 599-609.
53. Trusolino L, Comoglio PM, (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300.
54. Arai K, Lee SR, Lo EH, (2003) Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43: 254-264.
55. Cheng YC, Chen LM, Chang MH, Chen WK, Tsai FJ, et al. (2009) Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 325: 15-23.
56. Ning L, Wentworth L, Chen H, Weber SM, (2009) Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res 1: 358-366.
57. Qi R, An H, Yu Y, Zhang M, Liu S, et al. (2003) Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63: 8323-8329.